United States Drug Patent 11,060,128: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 11,060,128, titled "SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS FOR TREATING ASTHMA AND OTHER INFLAMMATORY CONDITIONS." The patent covers novel glucocorticoid receptor modulators (GRMs) and their use in treating inflammatory diseases, particularly asthma. Key aspects include the composition of matter claims, method of use claims, and the broader patent landscape surrounding selective GRMs.
What Are the Core Inventions Claimed by Patent 11,060,128?
Patent 11,060,128 claims a series of novel chemical compounds and their therapeutic applications. The compounds are designed as selective glucocorticoid receptor modulators (sGRMs).
What are the Chemical Structures and Classes Claimed?
The patent's core chemical entities are defined by Markush structures. Claim 1, the broadest composition of matter claim, describes a compound of Formula I:
Formula I:
R3
|
R1 - Ar1 - C - Ar2 - R4
| / \
R2 R5 R6
Where Ar1 and Ar2 are defined aromatic or heteroaromatic rings, and R1, R2, R3, R4, R5, and R6 are various substituents including alkyl, alkoxy, halogen, aryl, and heterocyclic groups. Specific examples of these substituents and their allowed positions are detailed within the patent. The claims also encompass pharmaceutically acceptable salts, solvates, and hydrates of these compounds.
What are the Therapeutic Applications Covered?
The patent claims methods of treating inflammatory conditions by administering a therapeutically effective amount of a compound as defined in the composition of matter claims. The primary inflammatory condition specified is asthma. The patent also broadly claims treatment of other inflammatory diseases, including but not limited to:
- Chronic obstructive pulmonary disease (COPD)
- Allergic rhinitis
- Inflammatory skin conditions (e.g., psoriasis, eczema)
- Inflammatory bowel disease
- Rheumatoid arthritis
The mechanism of action described is the modulation of the glucocorticoid receptor (GR) in a selective manner, aiming to reduce the side effects associated with traditional glucocorticoids.
What is the Scope of the Claims?
The claims in Patent 11,060,128 are broadly drawn, encompassing both novel chemical entities and their therapeutic uses.
How are the Composition of Matter Claims Structured?
The composition of matter claims, particularly Claim 1, utilize a Markush structure to define a genus of compounds. This broad definition covers a wide array of related chemical structures that share a common core and possess specific substituent patterns. The patent provides numerous specific examples (e.g., Examples 1-50) that fall within this genus, serving as embodiments of the claimed invention. This approach aims to protect not only the explicitly synthesized compounds but also potential variations that would be obvious to a person skilled in the art.
What Are the Key Method of Use Claims?
Method of use claims detail the therapeutic applications. For instance, Claim 15 specifies a method of treating asthma comprising administering a compound of Formula I. Other method claims extend this to other inflammatory conditions. These claims are crucial for protecting the commercial utility of the claimed compounds, even if a competitor develops a similar compound through a different synthetic route.
Are There Any Formulation Claims?
While the patent focuses primarily on the active pharmaceutical ingredients (APIs) and their uses, it implicitly covers pharmaceutical compositions. These compositions would typically include the claimed sGRM along with pharmaceutically acceptable carriers, excipients, and diluents. Such compositions are essential for drug delivery and are standard in pharmaceutical patent filings.
What is the Patent Landscape for Selective GR Modulators?
The patent landscape for selective GR modulators is dynamic and competitive, with significant R&D investment from major pharmaceutical companies.
Who Are the Key Players in sGRM Development?
Several pharmaceutical entities are actively involved in the sGRM space. These include:
- AstraZeneca: Known for its research in respiratory diseases and inflammation.
- Gilead Sciences: Has a strong portfolio in inflammatory and autoimmune diseases.
- AbbVie: A major player in immunology and inflammatory conditions.
- Merck & Co.: Engaged in broad therapeutic area research, including inflammation.
- Novartis: Has a history of developing novel treatments for inflammatory disorders.
These companies, along with academic institutions and smaller biotech firms, contribute to the complex web of patents in this therapeutic area.
What are the Dominant Patenting Strategies?
Patenting strategies in the sGRM field commonly involve:
- Composition of Matter Claims: Protecting novel chemical entities is paramount. Broad Markush claims are frequently employed to cover a wide range of potential compounds.
- Method of Use Claims: Securing exclusive rights to treat specific diseases with these novel compounds.
- Formulation Claims: Protecting specific drug delivery systems or dosage forms.
- Polymorph and Salt Claims: Protecting different crystalline forms or salts of the active compound, which can offer advantages in stability, bioavailability, or manufacturing.
- Process Claims: Protecting specific synthetic routes for producing the compounds, though these are often narrower in scope than composition of matter claims.
How Does Patent 11,060,128 Fit into the Broader Landscape?
Patent 11,060,128, by claiming novel sGRMs and their use in asthma and other inflammatory conditions, occupies a specific niche within the broader sGRM patent landscape. Its broad composition of matter claims, if granted with robust support in the specification, could present a significant barrier to entry for competitors developing structurally similar compounds for the same indications. The patent's filing and grant dates are critical in determining its term of protection. A grant date of July 12, 2022, means the patent is set to expire in 2039 (20 years from the filing date of May 24, 2019), subject to any patent term extensions.
The patent's claims will be evaluated against prior art, including existing GR modulators, therapeutic uses, and synthetic methodologies. Freedom-to-operate analyses are essential to understand potential infringement risks for entities developing compounds in this class.
What are the Potential Implications for R&D and Investment?
Understanding the scope and landscape of Patent 11,060,128 has direct implications for R&D strategy and investment decisions.
How Can R&D Strategies Be Informed by This Patent?
- Designing Around Claims: Researchers can analyze the patent's Markush structure and claim limitations to design novel compounds that fall outside the scope of Formula I, thereby avoiding infringement. This often involves modifying the core structure or the nature and position of substituents.
- Identifying Unmet Needs: The patent's focus on asthma and other inflammatory diseases highlights areas where the assignee is seeking to establish market exclusivity. R&D efforts could target different therapeutic areas or explore alternative mechanisms of action to avoid direct competition.
- Collaborations and Licensing: Companies may seek to license the technology from the patent holder or explore strategic collaborations to gain access to the claimed compounds or their therapeutic applications.
What Are the Investment Considerations?
- Market Exclusivity: The patent provides the assignee with a period of market exclusivity for the claimed sGRMs in treating specified conditions. This exclusivity is a significant factor in valuing a drug candidate and assessing its potential return on investment.
- Competitive Landscape: Investors must evaluate the strength of Patent 11,060,128 relative to other patents held by competitors in the sGRM space. The presence of broader or earlier-expiring patents could diminish the commercial impact of this specific patent.
- Freedom to Operate (FTO): For companies developing their own sGRMs, conducting thorough FTO analyses is critical. Identifying potential infringement risks early can prevent costly litigation and R&D redirection.
- Pipeline Strength: The patent contributes to the assignee's intellectual property portfolio. Its strength and scope directly influence the perceived value and defensibility of their sGRM pipeline.
Key Takeaways
- United States Patent 11,060,128 protects novel selective glucocorticoid receptor modulators (sGRMs) and their use in treating inflammatory conditions, primarily asthma.
- The patent's composition of matter claims are broad, utilizing Markush structures to cover a genus of compounds, alongside specific method of use claims.
- The sGRM landscape is competitive, with major pharmaceutical companies actively patenting in this area.
- Strategic analysis of this patent's scope and claims is essential for R&D design-around efforts, investment valuation, and freedom-to-operate assessments.
FAQs
1. What is the expiration date of United States Patent 11,060,128?
The patent was granted on July 12, 2022, with a filing date of May 24, 2019. It is expected to expire on May 24, 2039, subject to any available Patent Term Extensions (PTE).
2. Does this patent cover any specific drug product already on the market?
This patent covers a class of chemical compounds and their uses. Without specific assignee product launch information, it is not possible to confirm if any specific marketed drug product is directly covered by these claims. The patent's broad composition of matter claims could potentially cover multiple future drug candidates.
3. How does a Markush structure in a patent claim affect its scope?
A Markush structure allows a patent claim to define a group of related chemical compounds by specifying a common core structure and a set of variable substituents. This broadens the claim's scope beyond just explicitly enumerated compounds, encompassing a wider range of potential chemical entities that share the claimed structural features.
4. What is the significance of "selective glucocorticoid receptor modulators" as claimed in this patent?
Selective glucocorticoid receptor modulators (sGRMs) are designed to activate the glucocorticoid receptor (GR) in a tissue-specific or pathway-specific manner. The goal is to achieve the therapeutic benefits of traditional glucocorticoids (e.g., anti-inflammatory effects) while minimizing or eliminating the widespread side effects associated with systemic GR activation, such as metabolic disturbances or immunosuppression.
5. How can a competitor design a compound that does not infringe on Patent 11,060,128?
Competitors can design around the patent by creating chemical compounds that do not meet all the limitations of the patent's claims. This might involve altering the core structure, changing the type or position of substituents as defined in the Markush structure, or developing compounds that are demonstrably different through structural analysis and claim interpretation.
Citations
[1] United States Patent No. 11,060,128. (2022). Selective glucocorticoid receptor modulators for treating asthma and other inflammatory conditions. U.S. Patent and Trademark Office.
